17,924 results match your criteria Implantable Cardioverter-Defibrillators


A Comparison of Left Ventricular Lead Upgrade versus Continued Medical Care Among Patients Eligible for Cardiac Resynchronization Therapy at the Time of Defibrillator Generator Replacement: Predictors of Left Ventricular Lead Upgrade and Associations with Long-term Outcomes.

Heart Rhythm 2020 Jun 1. Epub 2020 Jun 1.

Cardiac Electrophysiology Section, Division of Cardiology, University of California-San Diego. Electronic address:

Background: Randomized trials evaluating cardiac resynchronization therapy (CRT) have excluded patients with pre-existing implantable cardioverter defibrillators (ICDs). The association of CRT upgrade with clinical outcomes in patients with a pre-existing ICD is unclear.

Objective: To examine a CRT-eligible population to evaluate clinical outcomes associated with CRT upgrade compared to patients who did not undergo CRT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hrthm.2020.05.032DOI Listing

Defibrillators in adult congenital heart disease: long-term risk of appropriate shocks, inappropriate shocks and complications.

Pacing Clin Electrophysiol 2020 Jun 4. Epub 2020 Jun 4.

Sydney Medical School, The University of Sydney, Camperdown, NSW, 2006, Australia.

Aims: Sudden cardiac death (SCD) accounts for up to 25% of deaths in the adult congenital heart disease (ACHD) population. Current guidelines for defibrillator implantation are either extrapolated from acquired cardiac disease or are based upon single lesion studies, predominantly Tetralogy of Fallot (TOF). Defibrillator-related morbidity appears to be substantially higher in ACHD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pace.13974DOI Listing

Validity Evidence of the Brazilian Version of the Florida Shock Anxiety Scale for Patients with Implantable Cardioverter Defibrillators.

Arq Bras Cardiol 2020 Jun;114(5):764-772

East Carolina University - Department of Psychology and Cardiovascular Sciences Greenville, North Carolina - USA.

Background: In spite of proven effectiveness of implantable cardioverter defibrillators (ICDs), shock therapy delivered by the device may result in increased levels of anxiety and depression, leading to deleterious effects on quality of life.

Objective: To carry out the translation, cross-cultural adaptation and validation of the Florida Shock Anxiety Scale (FSAS) scale into Brazilian Portuguese.

Methods: In this psychometric study, construct validity was performed by exploratory (EFA) and confirmatory (CFA) factor analyses, and by item response theory (IRT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.36660/abc.20190255DOI Listing

Assessing Candidacy for Primary Preventative Implantable Cardioverter-defibrillators in Pediatric Patients with Ion Channelopathies: Weighing the Risks and Benefits.

J Innov Card Rhythm Manag 2018 Sep 15;9(9):3297-3302. Epub 2018 Sep 15.

Department of Pediatric Cardiology, Cleveland Clinic Children's Hospital, Cleveland, OH, USA.

Inherited ion channelopathies have come to the forefront as a significant cause of sudden cardiac death (SCD) in pediatric patients with structurally normal hearts. Implantable cardioverter-defibrillator (ICD) placement can be a life-saving primary preventative therapy, but because of actors inherent in the pediatric population, careful thought must be given to the specific indications for placement in each patient. The most common inherited ion channelopathies are long QT syndrome, Brugada syndrome, and catecholaminergic polymorphic ventricular tachycardia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2018.090901DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252732PMC
September 2018

Tailored Anticoagulation for Thromboembolic Risk Reduction in Paroxysmal Atrial Fibrillation.

J Innov Card Rhythm Manag 2018 Apr 15;9(4):3116-3125. Epub 2018 Apr 15.

Harvard-Thorndike Electrophysiology Institute, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, affecting up to six million people in the United States and more than 35 million individuals worldwide. Thromboembolism, including stroke, represents the most common AF-related morbidity and mortality and data indicate that anticoagulation can mitigate this risk by 65%. Our understanding of thromboembolism in AF, however, remains incomplete, and the mechanisms by which AF increases thromboembolic risk are areas of ongoing investigation and debate. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2018.090404DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252665PMC

An "UninTENSional" Subcutaneous Implantable Cardioverter-defibrillator Shock.

J Innov Card Rhythm Manag 2018 Nov 15;9(11):3395-3397. Epub 2018 Nov 15.

Department of Cardiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada.

Subcutaneous implantable cardioverter-defibrillators (ICDs) (S-ICDs) are advantageous because they eliminate the need for transvenous leads. However, just like in the case of traditional ICDs, inappropriate shocks are an unwanted complication that may result following their placement. In this case, we discuss the mechanism of an inappropriate shock in a patient with an S-ICD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2018.091106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252790PMC
November 2018

The Effects of Catheter Ablation on Permanent Pacemakers and Implantable Cardiac Defibrillators.

J Innov Card Rhythm Manag 2017 Mar 15;8(3):2630-2635. Epub 2017 Mar 15.

Cardiology Department, Gill Heart Institute and VAMC, University of Kentucky, Lexington, KY.

Catheter ablation is a procedure that is frequently performed in patients with cardiac implantable electronic devices. Here, we review all of the potential interactions that can occur among patients undergoing catheter ablation while having implantable cardiac electronic devices, and discuss the precautionary measures to minimize such interactions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2017.080303DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252655PMC

Electrical Storm in Patients with Implantable Cardioverter-defibrillators: A Practical Overview.

J Innov Card Rhythm Manag 2017 Oct 15;8(10):2853-2861. Epub 2017 Oct 15.

Electrophysiology Section, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA.

Electrical storm (ES) is an increasingly common medical emergency characterized by clustered episodes of sustained ventricular arrhythmias (VAs) that lead to repeated appropriate implantable cardioverter-defibrillator (ICD) therapies. A diagnosis of ES can be made with the occurrence of three or more sustained episodes of VAs, or of three or more appropriate ICD therapies within 24 hours in patients with implanted devices. ES is associated with poor outcomes in patients with structural heart disease, particularly those with severe left ventricular dysfunction. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2017.081002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252660PMC
October 2017

Optimal Strategies to Reduce Inappropriate Implantable Cardioverter-defibrillator Shocks.

J Innov Card Rhythm Manag 2019 Apr 15;10(4):3623-3632. Epub 2019 Apr 15.

University of Colorado, Aurora, CO, USA.

Since the widespread implementation of implantable cardioverter-defibrillators (ICDs), their effectiveness in various situations has become well-established. However, despite many advances in both the technology and its utilization, inappropriate therapy remains a risk. Here, we review ICD shocks, their effect on outcomes, and current methods to reduce inappropriate therapy, finding overall that inappropriate ICD shocks are common and associated with adverse outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2019.100403DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252710PMC

Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus.

J Am Heart Assoc 2020 May 30:e012405. Epub 2020 May 30.

Duke Clinical Research Institute Duke University School of Medicine Durham NC.

Background There are conflicting data regarding the benefit of primary prevention implantable cardioverter-defibrillators (ICDs) in patients with diabetes mellitus and heart failure (HF) with reduced ejection fraction. We aimed to assess the comparative effectiveness of ICD placement in patients with diabetes mellitus and HF with reduced ejection fraction. Methods and Results Data were obtained from the Get With the Guidelines-Health Failure registry, linked with claims from the Centers for Medicare & Medicaid Services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.119.012405DOI Listing

Joint Position Paper of the Working Group of Pacing and Electrophysiology of the French Society of Cardiology and the French Society of Diagnostic and Interventional Cardiac and Vascular Imaging on magnetic resonance imaging in patients with cardiac electronic implantable devices.

Arch Cardiovasc Dis 2020 May 27. Epub 2020 May 27.

Clinique Pasteur, 31076 Toulouse, France.

Magnetic resonance imaging (MRI) has become the reference imaging technique for the management of a large number of diseases. The number of MRI examinations increases every year, simultaneously with the number of patients receiving a cardiac electronic implantable device (CEID). The presence of a CEID was considered an absolute contraindication for MRI for many years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acvd.2020.03.015DOI Listing

[Psychological adjustment in patients with an implantable cardioverter defibrillator: primary prevention and secondary prevention. A comparative study.]

Rev Esp Salud Publica 2020 May 27;94. Epub 2020 May 27.

Unidad de Arritmias. Servicio de Cardiología. Hospital Clínico Universitario Virgen de la Arrixaca. IMIB. Murcia. España.

Objective: The implantation of the Implantable Cardioverter Defibrillator (ICD) influences the psychological adjustment and the degree of subjective discomfort. The objective of this work was to analyze differences in psychological adjustment, fear of shocks and the degree of subjective discomfort derived from the illness depending on the reasons for implantation (primary vs secondary).

Methods: A sample of 82 patients with an ICD, for primary (58. Read More

View Article

Download full-text PDF

Source

A Unique Interplay of Multiple Predisposing Factors Culminating in a Catastrophic QT Prolongation.

Cureus 2020 Apr 21;12(4):e7757. Epub 2020 Apr 21.

Cardiology, Electrophysiology, State University of New York (SUNY) Upstate Medical University, Syracuse, USA.

Implantable cardioverter-defibrillators (ICDs) are used in patients without a reversible cause for long QT syndrome (LQTS) and secondary prevention in patients with LQTS-associated sudden cardiac arrest. We present a female patient with multiple reversible factors for QT prolongation, including the use of antidepressants, antidiarrheals, antiemetics, and antihistamines; chronic malabsorption from bariatric surgery; probable Gitelman syndrome and urinary losses of electrolytes, causing QT prolongation which leads to polymorphic ventricular tachycardia and a successfully resuscitated cardiac arrest. Our patient also had history suggestive of probable congenital LQTS with multiple childhood syncopal episodes and a history of seizures in first-degree relatives, further justifying the placement of an ICD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243073PMC

Impact of Diabetes Mellitus on Mortality and Hospitalization in Patients With Mild-to-Moderate Cardiomyopathy.

JACC Clin Electrophysiol 2020 May 26;6(5):552-558. Epub 2020 Feb 26.

Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address:

Objectives: This study examined the independent predictors of all-cause mortality, all hospitalizations, and cardiac hospitalizations in patients with mild-to-moderate cardiomyopathy (left ventricular ejection fractions [LVEFs] of 36% to 50%).

Background: Patients with severe cardiomyopathy have high rates of death. Implantable cardioverter-defibrillators (ICDs) improve survival in this setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacep.2019.12.008DOI Listing

Effect of Selective I Inhibition by XAF-1407 in an Equine Model of Tachypacing-induced Persistent Atrial Fibrillation (AF).

Br J Pharmacol 2020 May 20. Epub 2020 May 20.

Department of Veterinary Clinical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Taastrup, Denmark.

Background And Purpose: Inhibition of the G-protein gated acetylcholine-activated inward rectifier potassium (K ) current, I , may be an effective atrial selective treatment strategy for atrial fibrillation. Therefore, the anti-arrhythmic and electrophysiological properties of a novel putatively potent and highly specific I inhibitor, XAF-1407 (3-methyl-1-[5-phenyl-4-[4-(2-pyrrolidin-1-ylethoxymethyl)-1-piperidyl]thieno[2,3-d]pyrimidin-6-yl]azetidin-3-ol), were characterised for the first time in vitro and investigated in an in vivo equine, atrial-tachypacing-induced model of persistent AF in the following.

Experimental Approach: The in vitro ion channel pharmacological profile of XAF-1407, was investigated using cell lines stably expressing K 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bph.15100DOI Listing

Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator : Different viewpoints around the world.

Wien Klin Wochenschr 2020 May 20. Epub 2020 May 20.

HerzReha Bad Ischl, Gartenstraße 9, 4820, Bad Ischl, Austria.

The use of implantable cardioverter defibrillators (ICD) has been shown to improve survival in patients at risk of sudden cardiac death; however, due to the continuous risk of sudden loss of consciousness during arrhythmia or ICD intervention, they pose a potential risk to other road users while driving. A large number of opinions and recommendations from authorities and medical societies all over the world exist regarding driving restrictions after ICD implantation. This analysis provides an overview of the recommendations on driving restrictions from several countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00508-020-01675-0DOI Listing

Effect of physical and psychocognitive function and perceived health status on 12-month adverse cardiac events among implantable cardioverter-defibrillator recipients.

Heart Lung 2020 May 17. Epub 2020 May 17.

Mercer University, Georgia Baptist College of Nursing, Atlanta, USA. Electronic address:

Background: Post-implant recovery in patients with implantable cardioverter-defibrillators (ICDs) is often compromised because of reduced physical and psycho-cognitive function and poor health perception, leading to short event-free survival.

Objectives: To examine the effects of psychocognitive function, health perception, and ICD-related factors on 12-month cardiac events among ICD patients.

Methods: Using a prospective study design, ICD patients underwent baseline assessment and were followed for 12 months to assess cardiac events. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hrtlng.2020.04.010DOI Listing

[Quality of life in patients with implantable cardioverter-defibrillator from a salutogenic perspective : A qualitative study in cardiologic health service research].

Herzschrittmacherther Elektrophysiol 2020 May 19. Epub 2020 May 19.

Kardiologie, Angiologie, Pneumologie, Universitätsklinikum Heidelberg, Heidelberg, Deutschland.

Background: Evidence on disease-related quality of life (DRQoL) of patients with implantable cardioverter-defibrillators (ICDs) has been described heterogeneously. Disease-specific measures of DRQoL in ICD patients are lacking.

Objectives: The aim of this study was to gain a broader understanding of long-term DRQoL in ICD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00399-020-00692-wDOI Listing

Cost-effectiveness of remote monitoring of implantable cardioverter-defibrillators in France: a meta-analysis and an integrated economic model derived from randomized controlled trials.

Europace 2020 May 19. Epub 2020 May 19.

Scientific Department, ClinSearch, 110 Avenue Pierre Brossolette, 92240 Malakoff, France.

Aims: Cost-effectiveness data on the remote monitoring (RM) of implantable cardioverter-defibrillators (ICDs) compared to the current standard of care (SC) remains limited. This meta-analysis was performed to assess the economic burden, and to develop an integrated economic model evaluating the efficiency of the RM strategy vs. SC in the context of French healthcare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/europace/euaa082DOI Listing

Infection of cardiac prosthetic valves and implantable electronic devices: early diagnosis and treatment.

Acta Cardiol 2020 May 14:1-7. Epub 2020 May 14.

Department of Nuclear Medicine, Medical school, University Hospital of Ioannina, Ioannina, Greece.

There has been a recent rise in the use of implantable cardiac devices, mostly valves but also electronic ones, such as pacemakers, and implantable defibrillators. The increasing use of these devices had as a consequence the raised incidence of endocarditis, an infrequent but morbid complication of these procedures. Thus, early diagnosis of the implantable cardiac devices related infection and endocarditis became pivotal for appropriate management. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/00015385.2020.1761594DOI Listing

Exploring the acceptability of implantable defibrillators in patients with cardiac dystrophinopathy and carers.

Open Heart 2020 21;7(1):e001230. Epub 2020 Apr 21.

Department of Cardiology, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.

Objective: Unlike for patients with other forms of cardiomyopathies, those with severe ventricular dysfunction due to Duchenne muscular dystrophy (DMD) are not offered implantable cardioverter-defibrillator (ICD) therapy routinely. This prospective study aimed to determine the views of DMD-patients and their carers about discussing sudden death risk and their acceptance of ICDs.

Design And Setting: Adults with DMD (n=9) and parents/carers (n=9) participated in audio-recorded, 60-90 min focus group sessions (patients 2; parents/carers 2) conducted through either a face-to-face session at a neutral venue or a videoconference. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/openhrt-2019-001230DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204554PMC

Contemporary use of devices in chronic heart failure in the Netherlands.

ESC Heart Fail 2020 May 12. Epub 2020 May 12.

Department of Cardiology, Maastricht University Medical Centre, PO Box 5800, 6202 AZ, Maastricht, The Netherlands.

Aims: Despite previous surveys regarding device implantation rates in heart failure (HF), insight into the real-world management with devices is scarce. Therefore, we investigated device implantation rates in HF with reduced left ventricular ejection fraction (LVEF) in 34 Dutch centres.

Methods And Results: A cross-sectional outpatient registry was conducted in 6666 patients with LVEF < 50% and with information about device implantation available [74 (66-81) years of age; 64% male]. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ehf2.12740DOI Listing

Wearable cardioverter-defibrillator as bridging to ICD in pediatric hypertrophic cardiomyopathy with myocardial bridging - a case report.

BMC Pediatr 2020 May 11;20(1):207. Epub 2020 May 11.

Division of Pediatric Cardiology, Department of Pediatrics, Medical University Graz, Graz, Austria.

Background: There is only limited experience with wearable cardioverter-defibrillators (WCD) in pediatric patients. We report on the successful application of a WCD in an adolescent patient with hypertrophic cardiomyopathy and myocardial bridging.

Case Presentation: A 15-year-old girl presented with a history of recurrent syncope, dyspnea, and vertigo with exercise. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12887-020-02113-wDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212673PMC

The Relentless Pursuit of New Drugs to Treat Cardiac Arrhythmias.

Circulation 2020 May 11;141(19):1507-1509. Epub 2020 May 11.

The Lankenau Institute for Medical Research, Wynnewood, PA (P.R.K., V.M.R.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCULATIONAHA.119.045149DOI Listing

Endovascular Neuromodulation: Safety Profile and Future Directions.

Front Neurol 2020 24;11:351. Epub 2020 Apr 24.

Department of Medicine, Vascular Bionics Laboratory, Melbourne Brain Centre, The University of Melbourne, Melbourne, VIC, Australia.

Endovascular neuromodulation is an emerging technology that represents a synthesis between interventional neurology and neural engineering. The prototypical endovascular neural interface is the Stentrode, a stent-electrode array which can be implanted into the superior sagittal sinus via percutaneous catheter venography, and transmits signals through a transvenous lead to a receiver located subcutaneously in the chest. Whilst the Stentrode has been conceptually validated in ovine models, questions remain about the long term viability and safety of this device in human recipients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2020.00351DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193719PMC

Clinical utility of cardiovascular magnetic resonance imaging in patients with implantable cardioverter defibrillators presenting with electrical instability or worsening heart failure symptoms.

J Cardiovasc Magn Reson 2020 May 11;22(1):32. Epub 2020 May 11.

Department of Electrophysiology, Heart Center Leipzig at University of Leipzig, Struempellstr. 39, 04289, Leipzig, Germany.

Background: Data on the usefulness of cardiovascular magnetic resonance (CMR) imaging for clinical decision making in patients with an implanted cardioverter defibrillator (ICD) are scarce. The present study determined the impact of CMR imaging on diagnostic stratification and treatment decisions in ICD patients presenting with electrical instability or progressive heart failure symptoms.

Methods: 212 consecutive ICD patients underwent 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12968-020-00609-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212569PMC
May 2020
4.556 Impact Factor

Impact of different selection policies on subcutaneous ICD implants and therapies.

Pacing Clin Electrophysiol 2020 May 8. Epub 2020 May 8.

Department of Cardiology, King's College Hospital, London, UK.

Background: Patients with existing or anticipated indications for cardiac resynchronisation therapy (CRT), bradycardia, or anti-tachycardia pacing should not be offered subcutaneous defibrillators (SQIDs) but it remains unclear how clinicians should predict future need for these therapies.

Methods: We applied three SQID selection policies to data collected retrospectively from transvenous implantable cardioverter defibrillator (TV-ICD) implants: (a) approach A, SQID used in inherited channelopathies and idiopathic ventricular fibrillation only; (b) approach B, as above, plus all hypertrophic cardiomyopathy and grown-up congenital heart disease patients; (c) approach C, as above, plus primary and secondary prevention (for ventricular fibrillation only) of SCD in patients with QRS <150 ms. Approach C reflects current ESC and AHA/ACC/HRS guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pace.13936DOI Listing

The degree of translational and rotational movement of implanted pacemakers and cardioverter-defibrillators on coronal plane images in patients treated with radiotherapy for lung malignancy.

Med Dosim 2020 May 4. Epub 2020 May 4.

Department of Radiation Oncology, Carl Kirkland Cancer Center, Jackson, TN 38301, USA. Electronic address:

Malfunction of both implantable cardiac pacemakers and cardioverter-defibrillators as a result of exposure to therapeutic radiation is a known risk in radiation therapy. Although guidelines are available to minimize this risk for low energy beams, the guidelines rely on the estimated doses of ionizing radiation received by the device. Implicit in this calculation is that there is minimal day-to-day movement in the position of the device. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.meddos.2020.03.001DOI Listing

The First Steps Taken to Implement Palliative Care in Advanced Heart Disease: A Position Statement from Denmark.

J Palliat Med 2020 May 6. Epub 2020 May 6.

Danish Society of Cardiology, Copenhagen, Denmark.

According to the World Health Organization, palliative care must be available for everyone with life-threatening diseases. However, in daily practice the primary focus worldwide is on cancer patients. The aim of the article was to generate a national position statement as the first step in implementing palliative care in severe heart disease with focus on advanced heart failure, including tools to identify the need for and timing of palliative care and how palliative care could be organized in Denmark. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/jpm.2019.0566DOI Listing

Infections Associated with Resterilized Pacemakers and Defibrillators.

N Engl J Med 2020 05;382(19):1823-1831

From the Montreal Heart Institute, Université de Montréal, Montreal (T.F.K., M.-A.L., C.V., R.C., D.R., M.T., M.D., B.T., P.G.G., L.R., K.D., B.M., R.T., J.C.-T., L.M., P.K.); Instituto Nacional de Cardiologia, Ignacio Chavez, Mexico City (S.N.); the Dominican Institute of Cardiology, Santo Domingo, Dominican Republic (F.V.B.); Clínicas Médicas las Américas, Guatemala City, Guatemala (F.S.O.); and Cardiología Hospital General del Sur, Choluteca (N.E.L.O.), and Instituto Nacional Cardiopulmonar (G.S.M.) and Medicina Interna-Programación de Marcapaso Definitivo, Instituto Nacional Cardiopulmonar, Tegucigalpa (C.A.C.) - all in Honduras.

Background: Access to pacemakers and defibrillators is problematic in places with limited resources. Resterilization and reuse of implantable cardiac devices obtained post mortem from patients in wealthier nations have been undertaken, but uncertainty around the risk of infection is a concern.

Methods: A multinational program was initiated in 1983 to provide tested and resterilized pacemakers and defibrillators to underserved nations; a prospective registry was established in 2003. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1813876DOI Listing

Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study.

Eur Heart J 2020 May 6. Epub 2020 May 6.

Heart and Vascular Center, Semmelweis University Heart Center, Gaál József út 9, 1122 Budapest, Hungary.

Aims : The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy.

Methods And Results : We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/eurheartj/ehaa226DOI Listing

Causes of Failure to Capture in Pacemakers and Implantable Cardioverter-defibrillators.

J Innov Card Rhythm Manag 2020 Feb 15;11(2):4013-4017. Epub 2020 Feb 15.

Division of Electrophysiology, Department of Cardiovascular Medicine, University of Toledo Medical Center, Toledo, OH, USA.

The number of patients with implantable electronic cardiac devices is continuously increasing. As more pacemakers and implantable cardioverter-defibrillators (ICDs) are being placed, a basic understanding of some troubleshooting for devices is becoming essential. Loss of capture can be an emergent presentation for an unstable patient and can be encountered intermittently in hospitalized patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2020.110207DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192127PMC
February 2020

Lead Integrity Alert Triggered by T-wave Oversensing.

J Innov Card Rhythm Manag 2020 Feb 15;11(2):3983-3985. Epub 2020 Feb 15.

Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

T-wave oversensing (TWOS) is a relatively common occurrence in pacemakers and defibrillators that can lead to pauses and inappropriate implantable cardioverter-defibrillator shocks. We present a case of TWOS that triggered the Lead Integrity Alert (Medtronic, Minneapolis, MN, USA) without evidence of actual lead failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2020.110204DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192130PMC
February 2020

Strategies to Prevent Cardiac Implantable Electronic Device Infection.

J Innov Card Rhythm Manag 2020 Jan 15;11(1):3949-3956. Epub 2020 Jan 15.

Division of Cardiology, Department of Medicine, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY, USA.

The association between the risk of mortality and cardiovascular implantable electronic device (CIED) infections has been well-established in the literature. As CIED implantations have increased in frequency in the past few decades, the incidence of CIED-related infections has also risen. Given the morbidity, mortality, and health-care costs associated with CIED infections, the prevention of device-related infection is a critical goal. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.19102/icrm.2020.110102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192142PMC
January 2020

Early ICD lead failure in defibrillator systems with multiple leads via cephalic access.

J Cardiovasc Electrophysiol 2020 Jun 16;31(6):1462-1469. Epub 2020 May 16.

Leon H. Charney Division of Cardiology, New York University Langone Health, New York, NY.

Introduction: Implantable cardioverter defibrillators (ICDs) are proven to prevent sudden death in patients at elevated risk for sustained ventricular tachycardia or fibrillation. Complications related to ICD failure can stem from lead dysfunction, manufacturing defects, patient characteristics, or implantation technique. We conducted a review of all ICD leads implanted at our center from 2011 to 2017 to determine risk factors for premature lead failure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jce.14523DOI Listing

KCNQ1 Antibodies for Immunotherapy of Long QT Syndrome Type 2.

J Am Coll Cardiol 2020 May;75(17):2140-2152

Institute of Biochemistry and Molecular Medicine, University of Bern, Bern, Switzerland; Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland. Electronic address:

Background: Patients with long QT syndrome (LQTS) are predisposed to life-threatening arrhythmias. A delay in cardiac repolarization is characteristic of the disease. Pharmacotherapy, implantable cardioverter-defibrillators, and left cardiac sympathetic denervation are part of the current treatment options, but no targeted therapy for LQTS exists to date. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jacc.2020.02.067DOI Listing

Tachyarrhythmia Discriminator for Implantable Cardioverter-Defibrillators in Bundle Branch Block.

Heart Rhythm 2020 Apr 27. Epub 2020 Apr 27.

Department of Medicine, Medical College of Wisconsin, Milwaukee, WI. Electronic address:

Background: Inaccurate arrhythmia classification by implantable cardioverter-defibrillators (ICD) contributes to inappropriate shocks and increased healthcare utilization.

Objective: This study sought to evaluate the ability of a novel discriminator using far-field (FF) and near-field (NF) right ventricular lead electrocardiograms (EGMs), to differentiate ventricular tachycardia (VT) from supraventricular tachycardia (SVT) in patients with underlying conducted narrow QRS, right bundle branch block (RBBB) and left bundle branch block (LBBB).

Methods: ICD interrogations were reviewed, identifying subjects with tachycardia events at least 5 beats in duration with stable morphology and cycle length. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hrthm.2020.04.031DOI Listing

Subcutaneous implantable cardioverter defibrillator indication in prevention of sudden cardiac death in difficult clinical situations: A French expert position paper.

Arch Cardiovasc Dis 2020 May 22;113(5):359-366. Epub 2020 Apr 22.

Service de cardiologie, CHU de Rouen, 76000 Rouen, France.

The introduction of a new technology always raises questions about its place compared with the reference technology. The use of an implantable cardioverter defibrillator to prevent sudden cardiac death is now a widely proven technique, with a clear statement of its indication in the guidelines. More recently, a subcutaneous implantable cardioverter defibrillator has been introduced, and appears to be an attractive technique as it removes the need to implant a lead inside the right ventricle to treat the patient, which should dramatically decrease the risk of complications over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acvd.2020.03.011DOI Listing

Patient satisfaction with remote monitoring of cardiac implantable electronic devices: the VALIOSA questionnaire.

BMC Health Serv Res 2020 Apr 25;20(1):354. Epub 2020 Apr 25.

Department of Cardiology, Hospital Universitario de Araba, Vitoria, Spain.

Background: Remote monitoring of cardiac implantable electronic devices (CIEDs) has demonstrated substantial benefits. Treatment guidelines have therefore endorsed its use and is being increasingly adopted in the clinical setting, but the level of satisfaction they convey remains still unknown. We developed and validated a questionnaire to measure patient satisfaction with remote monitoring using Medtronic CareLink® Network and assessed its internal reliability and dimensional validity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12913-020-05216-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183665PMC

Electrogram morphology discriminators in implantable cardioverter defibrillators: A comparative evaluation.

J Cardiovasc Electrophysiol 2020 Jun 7;31(6):1493-1506. Epub 2020 May 7.

Cardio-Thoracic Unit, Bordeaux University Hospital (CHU), Pessac, France.

Background: Morphology algorithms are currently recommended as a standalone discriminator in single-chamber implantable cardioverter defibrillators (ICDs). However, these proprietary algorithms differ in both design and nominal programming.

Objective: To compare three different algorithms with nominal versus advanced programming in their ability to discriminate between ventricular (VT) and supraventricular tachycardia (SVT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jce.14518DOI Listing
June 2020
2.958 Impact Factor

Anesthesia teams managing pacemakers and ICDs for the perioperative period: enhanced patient safety and improved workflows.

Curr Opin Anaesthesiol 2020 Jun;33(3):441-447

Department of Anesthesiology, Pain and Perioperative Medicine, Icahn School of Medicine at Mount Sinai New York, New York, USA.

Purpose Of Review: There have been both technological and philosophical advances over the last decade regarding pacemakers and implanted cardioverter defibrillators (ICDs). Collectively, these devices are currently referred to as cardiac implantable electronic devices (CIEDs). Technological advances include the introduction of leadless pacemakers, subcutaneous defibrillators and cardiac event recorders, enhancements regarding compatibility of CIEDs for MRI scanning, the ability to interrogate devices remotely, and improved programming modes that preserve battery life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/ACO.0000000000000856DOI Listing

Sudden Cardiac Death in Children Affected by Cardiomyopathies: An Update on Risk Factors and Indications at Transvenous or Subcutaneous Implantable Defibrillators.

Front Pediatr 2020 3;8:139. Epub 2020 Apr 3.

Istituto Auxologico Italiano, IRCCS, Department of Cardiovascular, Neural and Metabolic Sciences, San Luca Hospital, Milan, Italy.

In the present paper, we will discuss the main cardiomyopathies affecting children with a specific focus on risk stratification and prevention of sudden cardiac death (SCD). We will discuss the main clinical features of hypertrophic cardiomyopathy (HCM), dilated and restrictive cardiomyopathies, left ventricular non-compaction (LVNC) and arrhythmogenic cardiomyopathy (AC), always highlighting their peculiarities in the pediatric age. Since sudden cardiac death may be the first manifestation of the disease, even in children, the identification of the specific underlying condition and of risk factors are pivotal to carry out the appropriate preventing strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fped.2020.00139DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7146705PMC

The price and value of implantable cardioverter defibrillators in hypertrophic cardiomyopathy.

Int J Cardiol 2020 Apr 2. Epub 2020 Apr 2.

Institute of Cardiovascular Science, University College London, Gower St, London WC1E 6BT, United Kingdom; St Bartholomew's Hospital, London EC1A 7BE, United Kingdom. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijcard.2020.03.082DOI Listing
April 2020
4.036 Impact Factor

Guideline-concordant-phenotyping: Identifying patient indications for implantable cardioverter defibrillators from electronic health records.

Int J Med Inform 2020 Jun 7;138:104138. Epub 2020 Apr 7.

Ahmanson-UCLA Cardiomyopathy Center, Ronald Reagan UCLA Medical Center, Los Angeles, CA, United States.

Background: Implantable cardioverter-defibrillators (ICDs) have been shown to reduce sudden cardiac death in appropriately selected patients, but they remain underutilized among indicated patients.

Objective: To develop a new approach to identifying guideline indications among patients implanted with ICDs by creating algorithms that extract data from electronic health records (EHR).

Methods: Published guidelines providing recommendations for ICD use were distilled into categories of diagnoses, measures, procedures, and terminologies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijmedinf.2020.104138DOI Listing
June 2020
2.004 Impact Factor

Implantable Cardioverter-Defibrillators in Trials of Drug Therapy for Heart Failure: A Systematic Review and Meta-Analysis.

J Am Heart Assoc 2020 Apr 15;9(8):e015177. Epub 2020 Apr 15.

Hospital Santa Cruz Centro Hospitalar Lisboa Ocidental Nova Medical School Faculdade de Ciências Médicas Lisbon Portugal.

BACKGROUND Medical therapy for heart failure with reduced ejection fraction evolved since trials validated the use of implantable cardioverter-defibrillators (ICDs). We sought to evaluate the performance of ICDs in reducing mortality in the era of modern medical therapy by means of a systematic review and meta-analysis of contemporary randomized clinical trials of drug therapy for heart failure with reduced ejection fraction. METHODS AND RESULTS We systematically identified randomized clinical trials that evaluated drug therapy in patients with heart failure with reduced ejection fraction that reported mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/JAHA.119.015177DOI Listing

Impact of Left Ventricular Ejection Fraction on Recurrent Ventricular Tachyarrhythmias in Recipients of Implantable Cardioverter Defibrillators.

Cardiology 2020 14;145(6):359-369. Epub 2020 Apr 14.

First Department of Medicine, University Medical Centre Mannheim (UMM), Faculty of Medicine Mannheim, University of Heidelberg, European Center for AngioScience (ECAS), and DZHK (German Center for Cardiovascular Research) partner site Heidelberg/Mannheim, Mannheim, Germany.

Objective: This study evaluates the impact of left ventricular ejection fraction (LVEF) on recurrences of ventricular tachyarrhythmias in recipients of implantable cardioverter defibrillator (ICD).

Background: Data regarding recurrences of ventricular tachyarrhythmias in ICD recipients according to LVEF is limited.

Methods: A large retrospective registry was used, including all consecutive ICD recipients with episodes of ventricular tachycardia (VT) or fibrillation (VF) from 2002 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000504876DOI Listing
April 2020
2.044 Impact Factor

Implementation, feasibility, and acceptability of quality of life therapy to improve positive emotions among patients with implantable cardioverter defibrillators.

J Behav Med 2020 Apr 14. Epub 2020 Apr 14.

Division of Bio-Behavioral Medicine, Medical University of South Carolina, 67 President Street, MSC 861, Charleston, SC, 29425, USA.

Implantable cardioverter defibrillators (ICDs) save lives, but often induce significant psychological distress among patients. Positive psychological constructs are associated with improved outcomes among cardiac patients. In this NHLBI-funded randomized controlled trial, one aim was to evaluate the feasibility and acceptability of a positive psychology intervention (Quality of Life Therapy; QOLT, n = 11), compared to a Heart Healthy Education (HHE) control (n = 10), among ICD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10865-020-00153-2DOI Listing

Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures.

Circ Cardiovasc Qual Outcomes 2020 Apr 14;13(4):e006105. Epub 2020 Apr 14.

Geriatrics Research, Education, and Clinical Care Center, Tennessee Valley Healthcare System VA, Nashville (M.E.M.).

Background: Several defibrillator leads have been recalled due to early lead failure leading to significant patient harm. Confirming the safety of contemporary defibrillator leads is essential to optimizing treatment for patients receiving implantable cardioverter-defibrillators (ICDs). We therefore sought to assess the comparative long-term safety of the 4 most commonly implanted ICD leads within the National Cardiovascular Data Registry ICD Registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/CIRCOUTCOMES.119.006105DOI Listing

Heart failure management in dialysis patients: Many treatment options with no clear evidence.

Semin Dial 2020 Apr 13. Epub 2020 Apr 13.

William B. Schwartz MD Division of Nephrology, Tufts Medical Center, Boston, MA, USA.

Heart failure with reduced ejection fraction (HFrEF) impacts approximately 20% of dialysis patients and is associated with high mortality rates. Key issues discussed in this review of HFrEF management in dialysis include dialysis modality choice, vascular access, dialysate composition, pharmacological therapies, and strategies to reduce sudden cardiac death, including the use of cardiac devices. Peritoneal dialysis and more frequent or longer duration of hemodialysis may be better tolerated due to slower ultrafiltration rates, leading to less intradialytic hypotension and better volume control; dialysate cooling and higher dialysate calcium may also have benefits. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/sdi.12878DOI Listing

Transesophageal and intracardiac ultrasound in arrhythmogenic right ventricular dysplasia/cardiomyopathy: Two case reports.

Medicine (Baltimore) 2020 Apr;99(15):e19817

5th Department of Internal Medicine, Cardiology-Rehabilitation.

Rationale: Two-dimensional echocardiography (2D echo) is a major tool for the diagnosis of Arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). However 2D echo can skip regional localized anomalies of the right ventricular wall. We aimed to determine whether transesophageal and intracardiac ultrasound can provide additional information, on the right ventricular abnormalities compared to 2D echo. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019817DOI Listing